Preface
Many of the trials with statins performed over the previous two decades have demonstrated the benefits of controlling LDL-cholesterol in the reduction of adverse cardiovascular events. However, statins have proven relatively little effect in correcting others forms of dyslipidaemia, as low levels of HDL-cholesterol. In this issue of European Heart Journal Supplements, an overview of the existing treatments and the future clinical strategies designed to improve cardiovascular outcomes is presented, addressing the role of techniques, such as neural network analysis, myocardial imaging and genotyping, in the progress of the accuracy of global cardiovascular risk determination. New pharmacological approaches include the use of Niaspan®, the prolonged-release formulation of nicotinic acid, in the management of dyslipidaemia. A special emphasis is given to the studies that support the combined use of lipid-lowering agents and HDL-cholesterol-raising drugs to induce regression of atherosclerosis and improve cardiovascular care.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||